Kontrola správného průběhu buněčného cyklu nádorovým supresorem p53 a inhibitory cyklin-dependentních kinas. Farmakologické inhibitory mimikující účinky přirozených regulátorů cyklu jako protinádorová terapeutika

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389030%3A_____%2F08%3A00322264" target="_blank" >RIV/61389030:_____/08:00322264 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15310/08:00005285

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Control of the proper cell cycle progression by products of the tumor suppressor gene p53 and inhibitors of cyclin-dependent kinases. Use of pharmacological inhibitors mimicking the action of cell cycle regulators for cancer therapy

Popis výsledku v původním jazyce

Cyclin-dependent kinases (CDKs) play a key rolein orchestrating the coordination of cell cycle progression in proliferating cells. The escape from the proper control of the cell cycle by upregulation of cyclins or aberrant activation of CDKs leads to malignant transformation. Proteins encoded by tumor suppressor genes such as p53 and cellular inhibitors of CDKs e.g. p16INK4a, p21Waf1/Cip1/Sdi, and p27Kip1 are able to counteract the deregulated cell cycle progression and to inhibit rapid (uncontrolled) cell proliferation. However, in the majority of cancer tissues tumor suppressors are inactivated or mutated. Virally encoded proteins e.g. E6 oncoprotein inactivate p53 by its accelerated proteolytic degradation. Therefore, use of synthetic compounds thatare able to inhibit the abnormally activated cyclin-CDK complexes and to reactivate p53 phosphoprotein became a new therapeutic option. The reactivation of p53 in malignant cells can inhibit cell cycle progression by multiple pathways an

Název v anglickém jazyce

Control of the proper cell cycle progression by products of the tumor suppressor gene p53 and inhibitors of cyclin-dependent kinases. Use of pharmacological inhibitors mimicking the action of cell cycle regulators for cancer therapy

Popis výsledku anglicky

Cyclin-dependent kinases (CDKs) play a key rolein orchestrating the coordination of cell cycle progression in proliferating cells. The escape from the proper control of the cell cycle by upregulation of cyclins or aberrant activation of CDKs leads to malignant transformation. Proteins encoded by tumor suppressor genes such as p53 and cellular inhibitors of CDKs e.g. p16INK4a, p21Waf1/Cip1/Sdi, and p27Kip1 are able to counteract the deregulated cell cycle progression and to inhibit rapid (uncontrolled) cell proliferation. However, in the majority of cancer tissues tumor suppressors are inactivated or mutated. Virally encoded proteins e.g. E6 oncoprotein inactivate p53 by its accelerated proteolytic degradation. Therefore, use of synthetic compounds thatare able to inhibit the abnormally activated cyclin-CDK complexes and to reactivate p53 phosphoprotein became a new therapeutic option. The reactivation of p53 in malignant cells can inhibit cell cycle progression by multiple pathways an

Druh

C - Kapitola v odborné knize

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/GA204%2F08%2F0511" target="_blank" >GA204/08/0511: Biologická aktivita syntetických inhibitorů cyklin-dependentních kinas</a><br>

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2008

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Trends in Cell Cycle Research

ISBN

978-81-308-0274-9

Počet stran výsledku

44

Strana od-do

—

Počet stran knihy

351

Název nakladatele

Research Signpost

Místo vydání

Kerala

Kód UT WoS kapitoly

—